DE60018761D1 - Therapeutische antikörper gegen das muc-1 antigen und verfahren zu deren verwendung - Google Patents

Therapeutische antikörper gegen das muc-1 antigen und verfahren zu deren verwendung

Info

Publication number
DE60018761D1
DE60018761D1 DE60018761T DE60018761T DE60018761D1 DE 60018761 D1 DE60018761 D1 DE 60018761D1 DE 60018761 T DE60018761 T DE 60018761T DE 60018761 T DE60018761 T DE 60018761T DE 60018761 D1 DE60018761 D1 DE 60018761D1
Authority
DE
Germany
Prior art keywords
muc
antigen
therapeutic antibodies
therapeutic compositions
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60018761T
Other languages
English (en)
Other versions
DE60018761T2 (de
Inventor
Ragupathy Madiyalakan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Altarex Medical Corp
Original Assignee
Altarex Medical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Altarex Medical Corp filed Critical Altarex Medical Corp
Publication of DE60018761D1 publication Critical patent/DE60018761D1/de
Application granted granted Critical
Publication of DE60018761T2 publication Critical patent/DE60018761T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
DE60018761T 1999-08-18 2000-08-18 Therapeutischer antikörper gegen das muc-1-antigen und verfahren zu dessen verwendung Expired - Lifetime DE60018761T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US14949299P 1999-08-18 1999-08-18
US149492P 1999-08-18
US16471499P 1999-11-11 1999-11-11
US164714P 1999-11-11
PCT/US2000/022890 WO2001012217A1 (en) 1999-08-18 2000-08-18 Therapeutic antibody against muc-1 antigen and methods for their use

Publications (2)

Publication Number Publication Date
DE60018761D1 true DE60018761D1 (de) 2005-04-21
DE60018761T2 DE60018761T2 (de) 2006-02-02

Family

ID=26846783

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60018761T Expired - Lifetime DE60018761T2 (de) 1999-08-18 2000-08-18 Therapeutischer antikörper gegen das muc-1-antigen und verfahren zu dessen verwendung

Country Status (7)

Country Link
EP (1) EP1204423B1 (de)
JP (2) JP2003519096A (de)
AT (1) ATE290879T1 (de)
AU (1) AU782569B2 (de)
DE (1) DE60018761T2 (de)
ES (1) ES2239032T3 (de)
WO (1) WO2001012217A1 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8038994B2 (en) 1996-05-15 2011-10-18 Quest Pharmatech Inc. Combination therapy for treating disease
WO2002058450A2 (en) 2000-12-22 2002-08-01 Dana-Faber Cancer Institute, Inc. Regulation of cell growth by muc1
US6627664B2 (en) * 2001-01-30 2003-09-30 Altachem Pharma Ltd. Perylenequinones for use as sonosensitizers
CA2436233C (en) * 2001-01-30 2010-10-05 Altachem Pharma Ltd. Perylenequinones for use with immunotherapy agents
WO2002076485A2 (en) 2001-03-27 2002-10-03 Biomira, Inc. Vaccine for modulating between t1 and t2 immune responses
AT500649A1 (de) * 2001-10-26 2006-02-15 Altarex Medical Corp Kombinationstherapie zur krankheitsbehandlung
BR0307206A (pt) * 2002-01-24 2004-12-21 Barnes Jewish Hospital Agentes de formação de imagem direcionados por integrina
DE10256900A1 (de) 2002-11-29 2004-06-24 Nemod Immuntherapie Ag Tumorspezifische Erkennungsmoleküle
DE10303664A1 (de) 2003-01-23 2004-08-12 Nemod Immuntherapie Ag Erkennungsmoleküle zur Behandlung und Detektion von Tumoren
US8129506B2 (en) 2003-10-24 2012-03-06 Genzyme Corporation Modulation of the interaction of MUC1 with MUC1 ligands
TW201204410A (en) 2004-04-01 2012-02-01 Oncothyreon Inc Mucinous glycoprotein (MUC-1) vaccine
WO2006081553A2 (en) * 2005-01-28 2006-08-03 Ramot At Tel Aviv University, Ltd. ANTI-MUC1 α/ß ANTIBODIES
CA2613327A1 (en) 2005-06-28 2007-02-08 Biomira, Inc. Method of treating patients with a mucinous glycoprotein (muc-1) vaccine
GB2442915B (en) 2005-08-10 2009-12-16 Quest Pharmatech Inc Perylenequinone derivatives and uses thereof
US8454991B2 (en) 2006-07-24 2013-06-04 Quest Pharmatech Inc. Method and device for photodynamic therapy
KR20170021375A (ko) 2006-09-10 2017-02-27 글리코토페 게엠베하 항체 발현을 위한 골수성 백혈병 기원의 인간 세포의 용도
EP1920781B1 (de) 2006-11-10 2015-03-04 Glycotope GmbH Zusammensetzungen die ein Core-1 positives Mikroorganismus enthalten und deren Verwendung zur Behandlung von Tumoren
WO2008097840A2 (en) 2007-02-02 2008-08-14 Dana-Farber Cancer Institute, Inc. Methods and compositions relating to the regulation of muc1 by hsf1 and stat3
WO2008097844A2 (en) 2007-02-02 2008-08-14 Dana -Farber Cancer Institute, Inc. Methods and compositions relating to the regulation of apoptosis by muc1 and bh3- containing proapoptotic proteins
CN102264765B (zh) 2008-10-28 2016-01-20 盐野义制药株式会社 抗muc1抗体
EP2281844A1 (de) 2009-07-31 2011-02-09 Glycotope GmbH MUC-1-Antikörper
EP2565268A4 (de) 2010-04-28 2013-10-09 Shionogi & Co Neuer muc1-antikörper
CA2825972A1 (en) 2011-02-24 2012-08-30 Oncothyreon Inc. Muc1 based glycolipopeptide vaccine with adjuvant
CA2844543A1 (en) 2011-08-22 2013-02-28 Glycotope Gmbh Microorganisms carrying a tumor antigen
JP2017009287A (ja) * 2013-11-11 2017-01-12 東ソー株式会社 前立腺癌と前立腺肥大症との識別方法
KR102262720B1 (ko) 2014-04-28 2021-06-08 이카가쿠 소우야쿠 가부시키가이샤 항muc1 항체 또는 그의 항원 결합성 단편 및 그 용도
US20190343953A1 (en) * 2017-01-27 2019-11-14 Glycotope Gmbh Anti-cancer treatments with an anti-muc1 antibody and an erbb inhibitor
EP3794041B1 (de) 2018-05-18 2023-07-12 Glycotope GmbH Anti-muc1-antikörper

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3698370B2 (ja) * 1992-04-13 2005-09-21 ダナ−ファーバー キャンサー インスティチュート インク 癌腫抗原用抗体
EP0649532B1 (de) * 1992-07-06 1997-11-12 Biomira, Inc. Photoaktivierung von proteinen zu konjugationszwecken
AU5615594A (en) * 1992-11-13 1994-06-08 Cancer Research Fund Of Contra Costa Polypeptides with specificity for neoplasias, kit, and diagnostic, vaccination, and therapeutic methods
DE19534630A1 (de) * 1995-09-18 1997-03-20 Max Delbrueck Centrum Monoklonale Antikörper gegen epitheliales Muzin (MUC1)
DK0910407T3 (da) * 1996-05-15 2003-06-16 Altarex Inc Fremgangsmåde og sammensætning til rekonformation af multiepitope antigener for at initiere et immunrespons
WO1998033470A2 (en) * 1997-01-10 1998-08-06 Altarex Corp. Substituted perylenequinones for use in photodynamic therapy
CA2319688A1 (en) * 1998-02-13 1999-08-19 Gunther Bastert Specific antibodies against mammary tumor-associated mucin, method for production and use

Also Published As

Publication number Publication date
AU782569B2 (en) 2005-08-11
ATE290879T1 (de) 2005-04-15
EP1204423B1 (de) 2005-03-16
WO2001012217A9 (en) 2002-06-27
JP2012046518A (ja) 2012-03-08
AU6921100A (en) 2001-03-13
EP1204423A1 (de) 2002-05-15
JP2003519096A (ja) 2003-06-17
DE60018761T2 (de) 2006-02-02
WO2001012217A1 (en) 2001-02-22
ES2239032T3 (es) 2005-09-16

Similar Documents

Publication Publication Date Title
DE60018761D1 (de) Therapeutische antikörper gegen das muc-1 antigen und verfahren zu deren verwendung
CY1120070T1 (el) Μεθοδοi θεραπευτικης αγωγης με τη χρηση συζευγματων αντισωματος εναντι-erbb-μεϋτανσινοειδους
NO331072B1 (no) Sammensetning som omfatter et angiogenese inhiberende middel og et anti tumor-immunoterapeutisk middel samt anvendelser av det samme.
DK1383785T3 (da) Rekombinant tumorspecifikt antistof og anvendelse deraf
IL163902A0 (en) Antibodies against cancer antigen tmeff2 and uses thereof
EP1476120A4 (de) Behandlungsverfahren unter verwendung von anti-cd22-antikörpern
PL377337A1 (pl) Humanizowane przeciwciało (H14.18) z mysiego przeciwciała 14.18 wiążące GD2 oraz jego połączenie z IL-2
DE69531679D1 (de) Für e-selectin und p-selectin spezifische kreuzreaktive monoklonale antikörper
IL139700A (en) Immunotherapeutic composition for the treatment of prostate cancer
AR035977A1 (es) Inmunoconjugados de anticuerpos cd44 citotoxicos.
DE69724428D1 (de) Humanisierte antikörper die an das gleiche antigen wie antikörper nr-lu-13 binden und deren verwendung in "pretargeting" verfahren
EP2298333A3 (de) Tweak Rezeptor
DE69703121D1 (de) Verfahren und zusammensetzungen zur verhinderung von entzündungen und angiogenese enthaltend säugetieren cd97 alpha untereinheit
UA29494C2 (uk) Гуманізовані антитіла, способи їх продукування, спосіб лікування хвороби крона, спосіб лікування розсіяного склерозу, фармацевтична композиція
DE69433406T2 (de) Antikörper gegen cd40
EE04752B1 (et) Monoklonaalne antikeha, seda tootev hübridoom ja antikeha kasutamine
BR9612619A (pt) Método e composição para reconformar antígenos multiepitópicos para iniciar uma resposta imunológica
ATE517340T1 (de) Sätze gegen kurze epitope gerichteter digitaler antikörper sowie diese verwendende verfahren
TW200517124A (en) Fully human antibodies against human 4-1BB
ATE490785T1 (de) Parathormon-antikörper und damit zusammenhängende verfahren
TR200103432T2 (tr) Engelleyici monoklonal VLA-1 antikoru ve enflamasyonlu hastalıkların tedavisinde kullanımı.
WO2000074729A3 (en) Alpha or beta emitters to fragments in radioimmunotherapy
CA2038578A1 (en) Delivery of agents
GB0102145D0 (en) Substances
DE3485712D1 (de) Monoklonale antikoerper gegen menschliche nierenkrebsantigene und verfahren.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition